BioLargo (NASDAQ:BLGO – Get Free Report) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for BioLargo and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1250 | 1568 | 44 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 15.66%. Given BioLargo’s peers higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.
Earnings & Valuation
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.00 |
BioLargo Competitors | $6.84 billion | $211.64 million | 66.85 |
BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares BioLargo and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -591.84% | 5.15% | -0.65% |
Risk and Volatility
BioLargo has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, indicating that their average stock price is 81% more volatile than the S&P 500.
Summary
BioLargo peers beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.